Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
RMD Open 2025;11:e005-21 Doi: 10.1136/rmdopen-2025-005521
Most patients vaccinated with RZV while using UPA 15mg QD and background MTX achieved satisfactory humoral and cell-mediated immune responses to recombinant zoster vaccine (RZV) at Weeks 4, 16 and 60. Winthrop et al. evaluated the immunogenicity of RZV through Week 60 in patients with RA who were receiving UPA 15mg QD and background MTX.
Factors such as age, RA severity, and the use or dose of concomitant corticosteroids did not affect humoral response to RZV. RZV was well tolerated, and no SAEs were reported within 30 days following vaccination. These findings support the potential of RZV as an effective long-term preventive strategy against HZ infections in RA patients who are at higher risk and receiving multiple immunosuppressive treatments.
Keywords:
